All News
EULAR 2024 kicked off with a fantastic debate between Janet Pope and David Liew - ‘JAK inhibitor special warnings: Can observational data debunk an RCT?’
A thought-provoking discussion summarising all aspects of the ongoing conversation on JAKi use in high-risk patients! https://t.co/MzW3jSSCfr
Links:
The Immune-Mediated Inflammatory Disease Forum IMIDforum ( View Tweet)
More data from Jak-pot, the real-world multinational RA study, this time looking at infection in 14 national registries
JAKi (vs TNFi) had no signal for general/serious infection (excluding HZ)
Somewhat reassuring post-ORAL Surveillance infection data
#EULAR2024 OP0092 @RheumNow https://t.co/ocAbc4NiV2
David Liew drdavidliew ( View Tweet)
Extra musculoskeletal manifestations (EMMs) in spondyloarthritis #EULAR2024 OP0085 @RheumNow https://t.co/yRxPmMYLxn
Dr. Antoni Chan synovialjoints ( View Tweet)
#EULAR2024 Please find my article on a preview of interesting abstract to look out for for #lupus #SLE therapies at this year’s congress @RheumNow
https://t.co/TEtrDWq3BF https://t.co/1zIIxsaeL2
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Increase in mSASSS over time was greater with increasing comorbidity burden. Increasing comorbidity burden is independently associated with greater radiographic progression #EULAR2024 OP0103 @RheumNow https://t.co/j7UblASUvC
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
SpA patients with IBD, compared to those without IBD, were less frequently male and more frequently HLA-B27 negative, had higher rates of uveitis and lower rates of psoriasis, exhibited more structural damage on SI joints in the METEOR cohort #EULAR2024 OP0085 @RheumNow https://t.co/c2KdzIumc4
Dr. Antoni Chan synovialjoints ( View Tweet)
Swap or Cycle? Study OP0081 show after failure to a first TNFi in patients with axSpA, the drug retention rate was higher in the cycle strategy compared to the swap (IL-17i) strategy. No difference in the disease activity between cycle and swap strategy #EULAR2024 @RheumNow https://t.co/vr5DvNOb21
Dr. Antoni Chan synovialjoints ( View Tweet)
Check out our coverage all #EULAR2024!
https://t.co/Be3O5npnbi https://t.co/fcg99zkbLi
Links:
Dr. John Cush RheumNow ( View Tweet)
Humira Clobbers Biosimilars in Battle for Part D Coverage
Researchers found nearly all Medicare Part D plans cover original adalimumab (Humira), but only about half cover approved biosimilars.
https://t.co/mpkypge1rE https://t.co/qRvtg4IM8c
Dr. John Cush RheumNow ( View Tweet)
Treatment intensification is associated with a higher ASDAS cut-off value than the recommended one (≥2.1). Rheumatologists may feel this is too stringent and use a higher ASDAS value for treatment intensification #EULAR2024 Abstract 0060 @RheumNow https://t.co/54vZUz7IEz
Dr. Antoni Chan synovialjoints ( View Tweet)
Nice idea from Erlangen: B cell then T cell suppression for ACPA+ RA. A tolergenic reset of sorts. Sounds interesting…
small study, but sadly no difference over ritux only. Does seem broadly safe though - maybe will be a strategy for another disease!
#EULAR2024 OP0069 @RheumNow https://t.co/mXUS4kpRCK
Links:
David Liew drdavidliew ( View Tweet)
In patients with bio-naïve r-axSpA, Ixekizumab treatment for 16 weeks decreased erosion scores and increased backfill scores, particularly in the IXE Q2W group, consistent with rapid tissue repair #EULAR2024 Abst OP0046 @RheumNow https://t.co/wMasGSZj2o
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
OP0053 #EULAR2024 @RheumNow #EULARBest
Effect of #RTX in preclinical #RheumatoidArthritis
RA-risk pts given 1 dose PBO or 1000mg RTX
RTX in RA-risk pts delayed onset of RA by 1yr; no benefit on QoL
Pts developing RA: RTX didn't alter PROs or disease severity when developing RA
Mrinalini Dey DrMiniDey ( View Tweet)
Genetic Risk scoring can predict adverse outcomes in #SLE #EULAR2024 @RheumNow https://t.co/g9kGdRkCOh
Bella Mehta bella_mehta ( View Tweet)
Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT:
data now out to 60w
good humoral and cellular response in most, even without MTX withheld
(& good safety too)
Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020 @RheumNow https://t.co/FqVCCwUJOg
Links:
David Liew drdavidliew ( View Tweet)
A potentially notable association between TNFi in PsA and an increased risk of ischemic heart diseases and heart failure compared to IL-17i treatment. Limitations of the study noted. This may be due to patient selection and channeling of patients to the TNFi group and more… https://t.co/Q2LotHZwjQ https://t.co/uwl6vBIMsb
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
Systematic Review of #SLE pregnancies in Latin America – 44articles, 4K patients, Hispanic/ Latino with increased preeclampsia when they have LN #EULAR2024 Abst#0986 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
AMPLIFIED study:
abatacept vs adalimumab in RF+ACPA+ early RA
Not a single blink of difference.
Maybe for high CCP titre but the inverse for low CCP.
Sadly, theoretical mechanistic benefit doesn’t always wash out. We’ll keep on looking for predictors #EULAR2024 OP0007 @RheumNow https://t.co/IswCub9lLn
David Liew drdavidliew ( View Tweet)
Digital technologies and health in #SLE can be integrated at several stages, but still a needs a bridge between #AI and #humanintellegence #EULAR2024 @Lupusreference @RheumNow https://t.co/1aN8QPgVWn
Links:
Bella Mehta bella_mehta ( View Tweet)
Treat to target in #lupus - difficult for many reasons.
Also may be too much of a restrictive strategy.
@Lupusreference talks about DORIS definition of remission- however mentions may be difficult to do in daily practice #EULAR2024 @rheumnow https://t.co/XqiubfOz2n
Links:
Bella Mehta bella_mehta ( View Tweet)